Drug Pipeline: NuGel, NuCerin, NuSepin, Papiliximab

Drug Development

Shaperon designs next-generation immunotherapies using inflammasome inhibitors, NanoMabs, and AI.

  • Drug Development
  • Pipeline

Pipeline

Pipeline

Inflammasome Inhibitor

  • Development
  • Optimization
  • Preclinical
  • Ph1
  • Ph2

Dermatology

    • GPCR19 Agonist

      NuGel

      Atopic Dermatitis

    • Development
    • Optimization
    • Preclinical
    • Ph1
    • Ph2

    NuGel

    Blocks the root cause of atopic dermatitis to restore skin health and reduce daily discomfort.

    • Competitiveness

      Demonstrated both superior efficacy and safety in clinical studies, while offering convenient topical application suitable for long-term management of chronic atopic dermatitis.

    • Market Outlook

      The global atopic dermatitis treatment market is projected to grow from approximately USD 13 billion in 2024 to USD 33 billion by 2030.

    • Unmet Need

      Current therapies are often limited by severe side effects or suboptimal efficacy relative to cost, making them unsuitable for long-term use. There remains a strong need for new, safer, and more effective treatment options.

    • Development Status

      Completed a Phase 2a clinical trial in Korea and successfully finished Part 1 of the U.S. Phase 2b study under FDA approval. The global Phase 2b Part 2 trial is currently in progress.

    • GPCR19 Agonist

      NuDifin

      Diabetic Foot Ulcer

    • Development
    • Optimization
    • Preclinical
    • Ph1
    • Ph2

    NuDifin

    Calms wound inflammation and accelerates the regeneration of new, healthy tissue.

    • Competitive Edge

      It promotes faster wound healing compared with existing therapies, shows superior collagen and epidermal regeneration, and can be used safely over the long term in patients with chronic conditions such as diabetes.

    • Market Opportunity

      The global market for diabetic foot ulcer treatments is projected to grow from approximately USD 8.8 billion in 2024 to USD 14.4 billion by 2032.

    • Unmet Need

      Current treatment options often show limited efficacy, frequent recurrence, and side effects, leading to delayed healing in many patients. There is a strong need for safer therapies that can restore inflammatory balance while accelerating tissue regeneration.

    • Development Status

      In preclinical studies, NuDifin has demonstrated wound contraction, de novo collagen formation, and complete epidermal restoration. Its safety profile has been confirmed in a Phase 1 clinical trial, and a Phase 2 clinical trial is currently in planning.

    • Next-generation
      GPCR19 Agonist

      NuRalin

      Atopic Dermatitis
      (Topical)

    • Next-generation
      GPCR19 Agonist

      NuAreatin

      Alopecia Areata

    • Development
    • Optimization
    • Preclinical
    • Ph1
    • Ph2

    NuAreatin

    Restores immune balance to reactivate hair follicles and bring new hope to areas of hair loss.

    • Competitiveness

      Normalizes scalp immune homeostasis and promotes follicle regeneration, enabling long-term treatment durability superior to existing therapies.

    • Market Outlook

      The global alopecia areata treatment market is projected to grow from approximately USD 3.8 billion in 2025 to USD 6.9 billion by 2034.

    • Unmet Need

      Current therapies are limited by side effects, cost, and high relapse rates, leaving major treatment gaps for severe and pediatric patients. Given the autoimmune nature of alopecia areata, there is a strong need for a long-term and safe therapy that focuses on restoring immune balance rather than broad immunosuppression.

    • Development Status

      NuAreatin was discovered using Shaperon’s AI-driven AIDEN platform and has demonstrated immunomodulatory efficacy in preclinical studies. Additional non-clinical evaluations are underway in preparation for clinical development.

Neurological Disorders

    • GPCR19 Agonist

      NuCerin

      Alzheimer’s Disease

    • Development
    • Optimization
    • Preclinical
    • Ph1
    • Ph2

    NuCerin

    A smart little pill designed to reduce neuroinflammation and protect precious memories.

    • Competitiveness

      An oral therapy that simultaneously targets amyloid-β (Aβ) and neuroinflammation, the two major causes of Alzheimer’s disease. It can be administered safely for long-term use without risks of brain edema or hemorrhage.

    • Market Outlook

      The global Alzheimer’s disease treatment market is projected to grow from approximately USD 6.4 billion in 2025 to USD 31 billion by 2034.

    • Unmet Need

      There is a high demand for a convenient and well-tolerated therapy with fewer side effects and proven efficacy not only in delaying but also in improving cognitive symptoms compared with existing treatments.

    • Development Status

      Efficacy has been validated in preclinical studies. Phase 1 clinical trial Part A has been completed in Korea, and Part B is currently in progress.

    • GPCR19 Agonist

      NuSepin

      CVA

Respiratory Diseases

    • GPCR19 Agonist

      NuSepin

      COVID-19

    • Development
    • Optimization
    • Preclinical
    • Ph1
    • Ph2

    NuSepin

    Rapidly alleviates excessive systemic inflammation in severe patients, accelerating recovery to everyday life.

    • Competitiveness

      Effectively controls broad-spectrum inflammatory responses, enabling safe use in high-risk patients regardless of COVID-19 viral variants. Its mechanism allows potential expansion to systemic inflammatory diseases such as sepsis and ischemic stroke.

    • Market Outlook

      The global market for SIRS therapeutics is projected to grow from approximately USD 1.4 billion in 2025 to USD 3.0 billion by 2035.

    • Unmet Need

      Current therapies for severe COVID-19 remain limited due to the lack of effective anti-inflammatory agents resilient to viral mutations and the serious side effects of existing drugs.

    • Development Status

      Received global Phase 2b/3 IND approval and completed a global Phase 2b clinical trial for severe COVID-19 patients with support from the Korea Drug Development Fund (KDDF). Indication expansion is currently underway for the treatment of systemic inflammatory response syndrome (SIRS) and ischemic stroke.

    • GPCR19 Agonist

      NuPulin

      IPF

    • Development
    • Optimization
    • Preclinical
    • Ph1
    • Ph2

    NuPulin

    Breaking the vicious cycle of inflammation-driven pulmonary fibrosis to help you breathe comfortably again.

    • Competitiveness

      NuPulin delivers efficacy comparable to existing therapies, while safely improving both pulmonary fibrosis and systemic inflammation without gastrointestinal adverse effects or hepatotoxicity.

    • Market Outlook

      The global idiopathic pulmonary fibrosis (IPF) treatment market is projected to grow from approximately USD 3.7 billion in 2024 to USD 5.5 billion by 2030.

    • Unmet Need

      Current therapies have limited ability to reverse advanced fibrosis and are often associated with a high risk of liver toxicity. Patients and physicians need new treatment options that can safely and effectively control fibrosis.

    • Development Status

      NuPulin has demonstrated efficacy in preclinical studies. It has completed Part A of a Phase 1 clinical trial in Korea, and Part B is currently in progress.

NanoMab

  • Development
  • Optimization
  • Preclinical
  • Ph1
  • Ph2

Hematologic Malignancy

    • Anti-PD-L1*CD47

      Papiliximab

      AML

    • Development
    • Optimization
    • Preclinical
    • Ph1
    • Ph2

    Papiliximab

    A new standard in leukemia treatment — achieving both reduced anemia risk and enhanced anti-tumor efficacy.

    • Competitiveness

      Papiliximab is a NanoMab-based bispecific antibody that simultaneously blocks PD-L1 and CD47, delivering superior anti-cancer activity without the anemia and other adverse effects commonly seen with conventional antibody therapies.

    • Market Outlook

      The global bispecific antibody market is projected to grow from USD 18 billion in 2025 to USD 485 billion by 2034.

    • Unmet Need

      Current leukemia treatments face low response rates with PD-L1 monotherapy and anemia caused by CD47-targeted agents. Papiliximab is designed to overcome both challenges, offering an innovative therapeutic option for hematologic malignancies.

    • Development Status

      Preclinical studies in rodents and non-human primates have demonstrated strong anti-tumor efficacy and excellent safety, and the program is preparing for Phase 1 clinical trials in patients with acute myeloid leukemia and other hematologic cancers.

Solid Cancer

    • Anti-CD3*4-1BB*TAA

      Ovizumab

      NSCLC

    • Development
    • Optimization
    • Preclinical
    • Ph1
    • Ph2

    Ovizumab

    A next-generation tumor-specific immunotherapy that boosts immune cell activity within the tumor microenvironment.

    • Competitiveness

      Ovizumab enhances tumor selectivity to minimize toxicity in normal tissues while improving bloodstream stability for balanced safety, potency, and durability. Its modular design enables application across multiple solid-tumor indications.

    • Market Outlook

      The immuno-oncology and multi-target antibody markets are rapidly expanding, particularly in solid tumors, driving strong demand for next-generation T-cell-activating platforms.

    • Unmet Need

      Existing therapies often suffer from cytokine-release syndrome, off-target toxicity, and limited efficacy or durability. Ovizumab is being developed to address these key limitations.

    • Development Status

      At the early preclinical stage, Ovizumab has shown robust tumor-suppressive activity in cancer cell models, demonstrating strong potential as a novel solid-tumor therapy.

    • Anti-CTLA-4*TAA

      Regtizumab

      Solid Cancer

    • Development
    • Optimization
    • Preclinical
    • Ph1
    • Ph2

    Regtizumab

    Revitalizing anti-tumor immunity while minimizing systemic side effects.

    • Competitiveness

      As a precisely engineered NanoMab, Regtizumab exhibits superior tissue penetration and selectively inhibits regulatory T cell function within the tumor microenvironment, enhancing immune activation while reducing systemic toxicity. It also holds strong potential for combination therapy with other immune checkpoint inhibitors.

    • Market Outlook

      Immuno-oncology continues to expand rapidly through combination regimens, and Treg-targeted therapeutics represent a highly promising and underserved segment.

    • Unmet Need

      Current treatments carry risks of systemic immune-related toxicities and limited efficacy due to resistance. Regtizumab aims to deliver precision immune modulation with improved safety and durability.

    • Development Status

      In early preclinical development, Regtizumab has shown restoration of immune activity through selective Treg suppression with a favorable safety profile.

    • LNP-mRNA

      Rbody

      Solid Cancer

    • Development
    • Optimization
    • Preclinical
    • Ph1
    • Ph2

    Rbody

    Improving both treatment outcomes and patient quality of life by reducing dosing frequency and cost.

    • Competitiveness

      Unlike conventional antibodies, NanoMabs’ small size enables the creation of LNP-mRNA therapeutics (Rbody). Our optimized NanoMab-based Rbody maintains long in vivo persistence and high stability even at lower doses, providing significant cost-effectiveness unattainable with traditional antibody drugs.

    • Market Outlook

      Excluding vaccines, the global mRNA-based therapeutics market is expected to grow from USD 19.6 billion in 2024 to USD 42.6 billion by 2034.

    • Unmet Need

      mRNA-based protein therapeutics still face challenges such as low expression and durability, manufacturing quality control, and safety issues—areas where Rbody offers innovative solutions.

    • Development Status

      In preclinical studies, Rbody maintained the same in vivo half-life as antibodies at less than half the dose, demonstrating strong potential for durable and efficient mRNA-based therapy.

NuGel

Addressing the Root Cause of Atopic Dermatitis
to Restore Skin Health and Reduce Daily Burden

  • Competitiveness

    • First-in-class GPCR19-targeting anti-inflammatory therapy, offering a novel mechanism of action beyond existing PDE4 inhibitors, JAK inhibitors, and steroid-based treatments
    • Simultaneous inhibition of sensitization (Priming) and activation, demonstrating differentiated anti-inflammatory efficacy compared to existing therapies
    • Improvement in key atopic dermatitis clinical endpoints, including EASI and vIGA, with no rebound observed after treatment discontinuation
    • GPCR19-mediated immune modulation minimizes systemic toxicity and adverse effects, supporting long-term use
    • Biomarker-based approach toward personalized treatment tailored to individual patient characteristics
  • Market Outlook

    • Approximately 170 million patients worldwide with atopic dermatitis (Prevalence: ~10% in children, ~3% in adults)
    • Global market size projected at USD 13 billion by 2025, with a CAGR of 16.4%, and expected to reach USD 33 billion by 2030
    • Limitations and adverse effects of existing PDE4 and JAK inhibitors are driving demand for new therapeutic options
  • Unmet Need

    • Lack of safe and effective long-term topical therapies for patients with mild to moderate atopic dermatitis
    • NuGel is positioned as a new standard-of-care candidate addressing this unmet need
  • Development Status

    • Phase 2a clinical trial completed in Korea, demonstrating improvement in EASI and vIGA scores as well as safety
    • Phase 2b clinical trial approved by the U.S. FDA (177 patients, 12-week treatment period) - ongoing
    • Global Phase 2b trial expected to conclude in 2026, with active out-licensing discussions underway
    • Preparation underway for commercialization as a prescription topical therapy
  • EASI*Eczema Area and Severity Index, a composite score evaluating the extent and severity of atopic dermatitis
  • EASI-50*≥50% improvement in EASI score from baseline
  • vIGA*Investigator’s Global Assessment, a 0-4 scale evaluating overall disease severity

Precision Medicine-Based Therapeutic Development:
Identification of Biomarkers Predictive of NuGel Responders

NuGel research data 1
NuGel research data 2

Distinct Efficacy of NuGel Confirmed in Biomarker-Positive Patients

NuGel research data 3
NuGel research data 4

Based on the results of Part 1 of a Phase 2b clinical trial,

NuGel shows great efficacy with atopic dermatitis
patients achieving 100% of EASI-50 in subgroup

NuGel research data 5
NuGel research data 6

NuDifin

Suppressing Inflammation at the Wound Site
to Accelerate Tissue Repair and Regeneration

  • Competitiveness

    • First-in-class GPCR19-targeting anti-inflammatory therapy that fundamentally modulates chronic inflammation and immune imbalance in non-healing wounds
    • Superior tissue penetration, safety, and cost competitiveness compared to growth factor-based therapies such as EGF and PDGF
    • Promotion of wound healing in chronic inflammatory conditions through inhibition of NLRP3 inflammasome activation and NETosis
    • Preclinical data demonstrating improved wound contraction and tissue regeneration compared to EGF
  • Market Outlook

    • The global diabetic population is projected to reach 850 million by 2025 and 1.2 billion by 2050
    • Approximately 19-34% of diabetic patients are expected to experience diabetic foot ulcers (DFUs) during their lifetime, with 9-26 million new cases annually
    • High rates of amputation and mortality associated with treatment failure are driving demand for safe and effective next-generation therapies
    • Limitations of growth factor therapies (low clinical success rates and high costs) are creating opportunities for inflammation-modulating wound therapeutics
  • Unmet Need

    • Existing growth factor-based treatments show variable efficacy, limited tissue penetration, high costs, and potential cancer risk
    • Therapeutic options remain limited for infected or recurrent DFUs
    • There is a lack of treatments capable of preventing recurrence through fundamental control of chronic inflammation
    • NuDifin is being developed as a first-in-class inflammation-modulating wound therapy to address these unmet needs
  • Development Status

    • In preclinical studies, NuDifin demonstrated superior wound healing and tissue regeneration efficacy compared to EGF
    • Phase 2 clinical trial entry targeted for 2026-2027
    • Confirmed topical stability, supporting development as a locally applied wound therapy

NuCerin

A Small but Intelligent Molecule
That Reduces Neuroinflammation and Helps Preserve Memory

  • Competitiveness

    • First-in-class GPCR19-targeting oral therapy offering superior convenience and safety compared to antibody-based treatments
    • Dual mechanism of action: Reduction of neuroinflammation + Promotion of amyloid-β (Aβ) clearance
    • No observed risk of ARIA (amyloid-related imaging abnormalities), including cerebral edema, unlike anti-Aβ antibody therapies → Suitable for long-term administration due to favorable safety profile
  • Market Outlook

    • Approximately 55 million patients worldwide with Alzheimer’s disease, projected to exceed 78 million by 2030
    • Antibody-centric markets face challenges due to high costs, injection burden, and safety concerns, creating unmet demand for alternative therapies
    • Rapid growth of next-generation oral and disease-modifying therapies focused on safety and convenience (estimated CAGR ~20%)
    • Increasing demand for long-term, orally administered treatments for early-stage and prodromal patients
  • Unmet Need

    • Existing antibody therapies suffer from high costs, safety risks, and administration inconvenience, limiting accessibility
    • Lack of orally available therapies suitable for long-term use in early-stage and mild cognitive impairment patients
    • Amyloid clearance-focused approaches alone are insufficient, highlighting the need for integrated modulation of neuroinflammation
    • NuCerin is being developed as a first-in-class, neuroinflammation-modulating oral therapy to address these gaps
  • Development Status

    • Phase 1 clinical trial ongoing in Korea (Part A completed, Part B ongoing)
    • Preclinical studies demonstrated: Improved cognitive function, Neuronal regeneration, Reduction of amyloid-β levels
    • Oral formulation with confirmed safety and stability, suitable for long-term administration

Reduction of Brain Amyloid-β Plaques and Neuroinflammation
following NuCerin Administration in an Alzheimer’s Disease Animal Model

NuCerin research data 1

Improvement in cognitive performance was observed
following NuCerin administration in an Alzheimer’s disease animal model.

NuCerin research data 2

NuSepin

Rapidly Suppressing Excessive Systemic Inflammation
to Accelerate Recovery to Daily Life in Critically Ill Patients

  • Competitiveness

    • First-in-class GPCR19-targeting intravenous anti-inflammatory therapy designed to fundamentally suppress hyperinflammatory responses, including cytokine storm
    • Simultaneous blockade of inflammatory initiation and amplification pathways, demonstrating greater efficacy than existing therapies
    • Rapid clinical response confirmed in Phase 2a, with fast onset of action and no severe adverse events observed
    • Broad potential for indication expansion, including: Severe viral pneumonia, Sepsis, COVID-19, CRS (Cytokine Release Syndrome) following immunotherapy
  • Market Outlook

    • Sustained demand for high-risk, hospitalized patient anti-inflammatory therapies, even in the post-COVID-19 era
    • WHO and CDC reports indicate persistently high mortality rates among critically ill patients, highlighting continued treatment gaps
    • Applicability across systemic inflammatory response syndrome (SIRS), pneumonia, and virus-induced hyperinflammation, supporting a market potential exceeding USD 10 billion
    • Repositioning as a rapid-response therapeutic platform for future pandemics and public health emergencies
  • Unmet Need

    • Antiviral therapies alone show limited ability to reduce immune-mediated mortality
    • Continued safety concerns with JAK/IL-6 inhibitors, including increased infection risk
    • Lack of effective treatments for severe COVID-19 and other hyperinflammatory conditions
    • NuSepin is being developed as a next-generation systemic anti-inflammatory therapy applicable across infectious and immune-mediated hyperinflammatory diseases
  • Development Status

    • Selected as a Korea Drug Development Fund (KDDF)-supported project
    • Global Phase 2b clinical trial completed

Superior improvement was observed in the NuSepin plus antiviral combination group compared to placebo.

NuSepin research data 1

NuPulin

Breaking the Vicious Cycle of Inflammation-Driven Pulmonary Fibrosis
to Help Patients Breathe More Comfortably Again

  • Competitiveness

    • First-in-class GPCR19-targeting oral therapy designed to reduce adverse events and improve long-term treatment convenience compared to existing therapies
    • Anti-fibrotic mechanism via inhibition of inflammasome activation, addressing not only disease progression but also promoting tissue recovery
    • Demonstrated efficacy comparable to existing treatments, with improvement in Ashcroft scores and reduced expression of fibrotic marker α-SMA in preclinical models
    • Selective modulation of immune cells, minimizing systemic adverse effects and supporting long-term administration
  • Market Outlook

    • Idiopathic Pulmonary Fibrosis (IPF) shows a 5-year survival rate of approximately 20%, with a global market size estimated at USD 2.5 billion
    • Among currently approved therapies, treatment discontinuation rates due to adverse events remain high (≈18%)
    • Aging populations are driving increasing prevalence and demand for safe, long-term oral therapies
    • Emergence of a new therapeutic market focused on inflammation–fibrosis dual-modulation mechanisms
  • Unmet Need

    • Existing therapies are largely limited to slowing disease progression, with minimal improvement in survival outcomes
    • Long-term treatment adherence is challenging due to gastrointestinal and other adverse effects
    • No approved therapies capable of achieving meaningful functional recovery and quality-of-life improvement
    • NuPulin is being developed as a next-generation oral therapy that simultaneously suppresses inflammation and fibrosis to address these unmet needs
  • Development Status

    • Phase 1 clinical trial ongoing in Korea (Part A completed, Part B ongoing)
    • In preclinical studies, NuPulin demonstrated suppression of pulmonary fibrosis and improvement in lung function (based on the bleomycin-induced fibrosis model)
    • Confirmed oral stability; under development as a once-daily oral formulation
  • Ashcroft Score* A semi-quantitative scale used to assess the severity of pulmonary fibrosis
  • α-SMA (alpha-smooth muscle actin)* A marker associated with myofibroblast activation and fibrosis progression

Reduction of Fibrosis-Related Markers
following NuPulin Treatment in Human Pulmonary Fibroblasts

NuPulin research data 1

Reduction in Histopathological Fibrosis Scores
following NuPulin Administration in an Idiopathic Pulmonary Fibrosis Animal Model

NuPulin research data 2
  • Vehicle A: Control group for comparator treatment
  • Vehicle B: Control group for NuPulin treatment
  • Bleomycin: A pulmonary fibrosis-inducing agent
  • Ashcroft Score: A semi-quantitative scale used to assess the severity of pulmonary fibrosis

Papiliximab

Setting a new standard for leukemia care by combining
enhanced anti-cancer efficacy with a reduced anemia risk.

  • Competitiveness

    • World’s first bispecific NanoMab simultaneously targeting PD-L1 and CD47
    • Maximizes tumor cell elimination by effectively neutralizing immune evasion mechanisms in cancer cells
    • Addresses anemia, the most critical adverse effect associated with conventional CD47 antibody therapies
    • Demonstrated favorable safety profile in non-human primate studies and superior tumor growth inhibition in vivo compared to existing antibodies
    • Small, high-stability nanobody format enables scalable manufacturing and reduced production costs
  • Market Outlook

    • The global bispecific antibody market is projected to grow from USD 18 billion in 2025 to USD 48.5 billion by 2034
    • The global acute myeloid leukemia (AML) market is expected to grow at a CAGR exceeding 10%, reaching approximately USD 10 billion by 2028
    • Despite strong interest, CD47-based immunotherapies have faced commercialization delays due to hematologic toxicities
    • Rapid expansion of the next-generation immuno-oncology market focused on safe immune activation
  • Unmet Need

    • Existing anti-PD-L1 monotherapies show limited response rates and resistance issues
    • Many CD47 antibodies have been discontinued due to severe anemia and hemagglutination-related toxicities
    • Strong demand for safe bispecific or novel-format immunotherapies
    • Papiliximab is positioned as a next-generation bispecific immuno-oncology candidate designed to overcome these limitations
  • Development Status

    • Preclinical development completed
    • In humanized mouse models of AML and lymphoma, Papiliximab demonstrated:
    • Superior tumor growth inhibition compared to comparator groups
    • More than five-fold improvement in overall survival
    • Non-human primate studies confirmed:
    • No red blood cell binding
    • No hemagglutination
    • Favorable pharmacokinetic (PK) stability
    • Strategically positioned as the first clinical entry candidate leveraging Shaperon’s bispecific NanoMab platform

Superior Tumor Growth Inhibition and Extended Survival
following Papiliximab Administration in a Humanized Lymphoma Mouse Model

Papiliximab research data 1
Papiliximab research data 2

Confirming Mitigation of Hemolytic Toxicity Associated with Conventional CD47 Antibodies

Papiliximab research data 3

Preparing

We are currently preparing the detail page.
Thank you.